Daré Bioscience faces a precarious financial outlook characterized by extreme revenue volatility and a reliance on non-recurring milestone payments to offset high fixed operating costs. While the company maintains a portfolio of clinical-stage assets, the rapi...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.20+32.6% vs -$0.30 | $187,546+11150.5% vs $1,667 |
Q2 2026 May 14, 2026 | -$0.20+39.4% vs -$0.33 | $152,455+464.6% vs $27,000 |
Q2 2026 Mar 26, 2026 | -$0.02+91.7% vs -$0.24 | $1M+36.2% vs $751,500 |
Q4 2025 Nov 13, 2025 | -$0.28+15.2% vs -$0.33 | $2,262-99.7% vs $765,000 |
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%
View the video webcast here
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
Video webcast now available here
Benchmark DARE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Dare Bioscience, Inc. (DARE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.81 | $12.02M | -0.67 | 10429.36% | -1300.66% | -471.37% | — | |
| $4.92 | $199.75M | 4.03 | 55.25% | 45.97% | 10.97% | — | |
| $3.28 | $20.72M | -2.71 | 125.12% | -115.49% | -61.39% | — | |
| $10.97 | $123.75M | 29.65 | 30.75% | 17.63% | 8.32% | — | |
| $74.43 | $1.69B | 22.42 | 43.78% | 10.82% | 19.19% | — | |
| $12.54 | $1.05B | -23.66 | — | — | -36.15% | — |
Dare Bioscience, Inc. (DARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Dare Bioscience, Inc. (DARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Aug 13, 2026·SEC
Jul 24, 2026·SEC
Get notified when DARE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dare Bioscience, Inc. (DARE) stock FAQ — growth, dividends, profitability & financials explained
Dare Bioscience, Inc. (DARE) reported $1.4M in revenue for fiscal year 2025. This represents a 348% increase from $0.3M in 2011.
Dare Bioscience, Inc. (DARE) grew revenue by 10429.4% over the past year. This is strong growth.
Dare Bioscience, Inc. (DARE) reported a net loss of $11.0M for fiscal year 2025.
Dare Bioscience, Inc. (DARE) has a return on equity (ROE) of -471.4%. Negative ROE indicates the company is unprofitable.
Dare Bioscience, Inc. (DARE) had negative free cash flow of $11.8M in fiscal year 2025, likely due to heavy capital investments.
